Proteomic profiling reveals C1QA and COMP as promising plasma biomarkers for early detection of pancreatic neuroendocrine tumors

#4084

Introduction: PanNETs (pancreatic neuroendocrine tumors) have distinctive clinical features and may vary in aggressiveness. Current diagnostic methods, including biochemical tests and imaging techniques, lack the required sensitivity and specificity, with invasive and expensive procedures. The urgent need for specific, cost-effective biomarkers for early PanNET screening and diagnosis is emphasized, especially in developing countries.

Aim(s): To identify specific proteins through proteomic analysis for early detection and diagnosis of pancreatic neuroendocrine tumors (PanNET).

Materials and methods: 38 samples were collected - 28 from PanNET patients and 10 controls. Mass spectrometry-based proteomic profiling was conducted in 12 subjects (3 controls; 5 Grade I, 4 Grade II PanNET patients). Proteome Discoverer processed raw files, and dysregulated proteins underwent pathway analysis using STRING and DAVID tools. Antibody-based validation was done for C1QA, COMP, HSP90, FN1, and ITGA2B via western blotting. Human C1QA and COMP were quantitatively measured using ELISA kits in PanNET and controls.

Conference:

Presenting Author: Gorai P

Authors: Gorai P, Bharti P, Surabhi A, Kumar S, Rajacharya G,

Keywords: Pancreatic neuroendocrine tumor, Proteomics, Biomarker, Plasma,